Fig. 52

	59		55			\$	4344 34473944344	4			38		29		ដ		ເກ		
arp31	эгр30	arp28	arp26	3rp25	arp16	3rp 14	arp13	arp12	arp11	arp10	edit e	3/p4	arp_1	arp_16	arp_17	arp 24	arp_25	묽	
FIV	CDHLRY	DEH	FLY	တ္ထ	YQH YQH	栗	FGHRSY	<u>~</u>	DGLPSV	EQY	E E E	유 유	A.S	ΑV	AT	71	Ş	Diversity	Diversity
31V=38A=40F=40Y, 31	30H=37L=38L=85A=85V	28H=30G		Q=R		m=x	13F=31F=31I		11G=13Y=14E=14=K25 Q=25R=30L, 11S=12K=12T, 11P=13R	10E=31V=38A=40Y= (166Q)=(166R)	9K=11D=26Y=28H=30G	Q=20	A=S	A=V	A=T	***************************************	大# 为		Equivalence
						* My control of the c						.,,		, , , , , , , , , , , , , , , , , , , ,	Section			Total	Total (+) Vs (-)
				Q > 4 * * * * * * * * * * * * * * * * * *		0,000,000,000,000,000,000,000,000,000,000,000			V(-)>hetero					A(-)>hetero Vhomo>hetero	Ahomo>hetero T(-		K(-)>hetera Rhamo>hetera	Total	Total (homo)
FV77.8	cctego	DE69.2	LY70.2		HQ71.50	EE66.2	HY100, FR71.6	KX66.5	GV100 LL1000	EY83.3	KW74.2	QR68.3	SS83.36	VV78.8	AA76.6	F166.7	RR78.8		Total
• • • • • • • • • • • • • • • • • • • •			••••			00000					•••				**4 29 ** 17	F(-)>(+)		Stomach	Total (+) vs (-)
<u> </u>			Lhelero -		Qhetero> homo				Whetero >()	,								Stomach	Total (homo)
FV76.2	001000	DE69.4	LY80.3		HQ830	EX80	SY100, GR75.4	TT70.7	TT100	EY75	KW75.8	RR68.1	SS100	W71.4	AA67.8	6.0911	RR71.4		Stomach
[+]>(-)			• • • • • • • • • • • • • • • • • • • •			9	F(+)>(-)						A(+)>(_) S(-)>(+)		38661-31			Other cancers	Total (+) vs (-)
Fheteroshomo			Fhetero×homo			7,000	Pheteroxi J Rheleroxhamo Shelero (-)xhamo		Pheteroxhoma				A. Shomohetero>>		*****		. 9	Other cancers	Total (homo)

Fig. 53

107	6	1 03				8	99	8	89	87		සු	76	68	67		66	62	ගු				
arp78	arp77	arp74	arp73			erp71	arp70	arp67	: arp60	arp58		arp57	arp47	arp40	arp38	,	arp37	arp33	arp32		GR R		harman
Ş	목	AELQR	AG			AEKR	DQR	<u></u>	HAY	ΑE		: ADSV	FΥ	Ę	ALV		FLNSY	Į	¥		Diversity	Diversity	
` V=Y	N=T	: R=N	73A=73G=74R=74N= 77N=77T		•••				:	A=E		****	; F=Y	F=Y		. 15.	F=S	#Z	H=Y		• • • •	Equivalence	a) Augustus
•••					•••					e después de después de la constante de después después de después			• • • • •							· dyryk di e daljede je krande je jegrafije is dyratije je berak deljekaris.	Total	VS (-)	Prognosis
						Ki-i>hetero		***		· · · · · · · · · · · · · · · · · · ·		Shetero (-)>homo								医骨骨 化苯甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基甲基	Fotal	(nomo)	Prognosis
VY67.1	TT66.4	LR80	AA66.3	AE72.6	ER67.2	AR63.5	DD69.4	F168.5	: HS73.7	AE67		AV73.70	FY67.4	: FY73.1	C0811		LT800	NN66.7	: HY66.9	a projekt skul krysk is de projekt de projekt de projekt is de projekt i		Otal	Prognosis
		***				*		****		A PARTY OF THE REAL PROPERTY OF THE PARTY OF			. , , , ,					.,		· · · · · · · · · · · · · · · · · · ·	Stomach	10(8) (+) VS (-)	Prognosis
		•••	.,,,			K-l>hetero				A 2017 A 2 2017 A 2 3 3 3 5 5 5 6 6 7 8 8 9 7 7 7 8 9 7 7 7 8 9 7 7 7 8 9 7 7 7 8 9 7 7 7 8 9 7 7 7 8 9 7 7 7 8 9 7 7 8 9 7 7 8 9 7 7 8 9 9 7 8 9 9 7 8 9 9 7 8 9 9 9 9											Stomach	lotal (nomo) Stomach	Prognosis
\Y68.6	FT68.2	AQ1000	AA68.1			m で う	DD72.7	FI72.2	HY68.4	AE71.1	SV72.5	AD72.5,	6.89 <i>X</i> X	FY71.6	AV78.8		FS73.4	HH71.4	8944			Stomach	Prognosis
								***		The state of the s						• •		,		cancers	Other	(-)	Prognosis
					homo	A Enelero>		***			nomo	Shelero				heterophomo	m ::	*****			Other cancers	i otai (nomo)	Prognosis

Fig. 54

		4	262	260	218	210	209		195		178	17.1	169	162			133		125	115	114		••••		
		1.7	aro233	arp231	arp 189	arp 181	arp 180		arp 166	arp 164	arp149	arp142	arp140	arp133	********	arp120	arp104	arp98	erp96	arp86	arp85		DR.	Thus to the	
survived	<u>A</u>	·	고	ညီ	RS	Z	LV		QR R	FV	НОҮ	K	AT	50	,; ,;	NS S	AS	m X	ЕНОҮ	GV	AV	***************************************	Diversity	Diversity	**
			₩ ₩	P=Q	X) ()		\{ =\/		Q=R		H=O	M=V		133L=133R=142M=142V		SEN	A≈S	98E=98K=104A=142V		: G-V	A=V		•	Equivalence	
	***************************************			,,,,,				و ميارد و د د د د د د د د د د د د د د د د د د													# 44		Total	Total (+) Vs (-)	Prognosis
		******		,,,,					****			,		, , , , , , , , , , , , , , , , , , ,)>hetero Shomo>n etero	Z.						· · · · · · · · · · · · · · · · · · ·	Total	Total (homo)	Prognosis
LL(5)	DR11GLGV		: 1167.4	QQ66.7	SS100	1167.3	LL75.1	ي ميدود كا م	RR67		HH68.1	VV67.5	7171.5	RR67.5		NN77.9	AS70.5	EK68.5	EE100	: GG68.5	AA80	· · · · · · · · · · · · · · · · · · ·	•••	Total	Prognosis
			## ***																		Pa		Stomach	Total (+) vs (-)	Prognosis
		etero (-)	R Thomash	,	***************************************				.,,,,							*****	11.00				6 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	***	Stomach	,	1
C(4)	DR30CLC	3	RR78.2	QQ67.9	SS100	FT69	LL70.1	RR68.6	QR68.6,		HH70.8	MM69.7	3774.1	LL69.7		NN72.9	AS72.1	EK72.1	EE100	VV69.4	VV68.1		•••	Stomach	Prognosis
				,								V(+)>(-)		ア(+)マー								cancers	Other	Total (+) vs (-)	Prognosis
		>homo	R Thelero (-)		***************************************					***************************************									C(-) hetero>homo			TO THE TOTAL PROPERTY OF THE PARTY OF THE PA	Other cancers	Total (homo)	Prognosis

Fig. 55

	Cospectation of the second of	7 ((-)>(+)	(55.5) F1(60.7)) A Ade community	V(-)2(+)	DOAL	0Y. 31(F=1)	114	apo
		Immunotherap y R(-)>(+)	I	Immunotherapy R(-)>hetero	no adjuvant therapy H(+)×(-) Immunotherapy R(-)>(+)	CC100	30H=37L=38L=8 5A=85V	CGHLR Y	arp30
Immunotherapy EH (68.6)	Immunotherapy Ehelera (-) >homo			Immunotherapy Ehelero I. Phomo	.,,	EE83,3	28H≃30G	DEH	arp28
Immunotherapy LY66 7	Chemotherapy Linetera (L.)>homo Immunotherapy Linetera (L.)>homo		no adjuvent therapy FL(87), Immunotherapy FL(61.4)	Chemotherapy Linetero-(-) homo Immunotherapy Linetero (-) ~homo	Chemotherapy 26Li+j>(-)	LL100		ξ	arp26
							Q=R	QR	arp25
						QY100		ΥQΉ	arp16
					.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	EE63.5	m#	9	arp14
	Immunotherapy Hhomo ((-))>hetero		no adjuvant therapy GH(89.9) Immunotherapy FS(81.9)		Immunotherapy Shetero> (-) homo	FR74.20	13F=13F=318	FGHRS Υ	arp13
						KK64.2		ኋ	arp12
	Immunotherapy Vnomo.((-)) >hetero		no adjuvant therapy DS(83.4)DV(79.6) Immunotherapy DP (84.6)	Immunotherapy Vnomo ((+))>hetero		FF.1000	11G=13Y=14E=1 4=K25Q=25R=3 0L. 11S=12K=12T, 11P=13R	V V	arp11
	Immunotherapy E(-) >hetero	Immunotherap y E(-) >(+)		immunotherapy £(+) >hetero	Immunotherapy E(-)>(+)	EY100	10E=31V=38A=4 0Y=(166Q)=(166 R)	EQY	arp10
Immunotherapy KW 84 6	Immunofherapy E++, (homo)=hetero		Immunotherapy KW (86.7)			KW71.2	9K=11D=26Y=28 H=30G	EKW	arp9
						QQ69.3	Q-R	QR	arp4
						AA90 90	A≕S	AS	arp1
						¥100	A=V	AV	arp 16
			Immunotherapy AA 71.4			AA100	A=T	AT	arp 17
						FL100	B		arp 24
						RR100	X I		arp 25
	Stomach	Stomach		Total	Total			Diversit	DR
Stornach cancer	Total (homo)	Total (+) vs (-)	All cases	Total (homo)	Total (+) vs (-)	Other cancers	Equivalence	Diversit v	
Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect	Prognosis			

(Cut-off data added as was present in Figure as originally filed)

Fig. 56

arp78	arp77	arp74	arp73	arp71	arp70	arp67	агр60	aro58	arp57	arp47	arp40	arp38	агр37	arp33	arp32	2	
≨	TN TN	AELOR	AG	AEKR	DOR	7	HAY	AE	ADSV	FΥ	FΥ	ALV	FLNSY	¥	HY	Diversity	and the same and the same
. γ=γ	Z=T	R _z	73A=73G=74 R=74N=77N= 77T					: A=E		; F=Y	₽≠γ		χ. 30	H=N	γ=H=	Equivalence	
VV69.3	NT83.3	ER1000	AG85.6,	KR78 80	RR69.4	FF72.4	HS88.9	AA63.5	AV88.90	FY67.3	FY75	LL 100	FL8330	HN64.5	HY64.8	Coner cancers	Piogross
		Cheriotherapy E(+)-(+) firmunotherapy E(+)-(-)		no adjuvant therapy Ki- (>!+)	Chemotherapy Rilly(+)	Immunotherapy I(-)>(+) Chemotherapy I.(-)>(+)	Chemotherapy H ()-(+)		Chemotherapy A. (-y+)		Immunotherapy Y(-)-(+)	Immunotherapy A(->-(+), no adjuvant therapy L(+)>-(-)	Chemotherapy F (+>+) mo adjuvant therapy L (+>>+ Immunotherapy N(+>>+)		3 U.S.	10181 (+) VS (-)	Treatment Effect
		Immunotherapy Anatoropy Jehanno Immunotherapy Elektro fronto-ty		no adjuvant therapy Abelero (1) inhomo Ebelero (1) jinhomo		Immunotherapy I(-)>homo, hetero, no adjuvant therapy Lhetero>(-),homo, Chemotherapy L(-)>hetero,homo	ما الما الما الما الما الما الما الما ا		no adjuvant therapy Shetero ((-))-homo	.,,	Introductivitapy Fhomoshetero Implicationatherapy Yi Integero	Immunotherapy Al- Inhelero	Chemotherapy Fi shatera humo Immunotherap Nivetero (homoso)		Clay	(nomo)	Treatment Effect
		Immunotherapy AE(87.9)		no adjuvant therapy RR(81.8) Immunotherapy ER(73.7)		no adjuvant therapy IL(82.8), Chemotherapy FI(63.4), Immunotherapy FL(68.4)	Chemotherapy YY (56.8)		no adjuvant therapy SV(\$2.2) Chemotherapy DD(60.3) Immunotherapy AD(76.2)		Immunotherapy FF(57.5)		Chemotherapy LY(70.9), Immuratherapy NS(72.5)			All cases	Treament Effect
	Chemolierapy Nobel 1	Chemotherapy Rule(+)	Chemotherapy G(1574)	no adjuvani therapy K (> (+)				· · · · · · · · · · · · · · · · · · ·				Immunotherapy Au-trains		M-1-(+)	OWINGE	(O(2) (+) vs (-)	Treatment Effect
	Chemotherapy Ni Phetara Chemotherapy Thomp-thetero	Immunotherapy Ahelero(Jhoria, Chemotherapy) Phalero	Chemotherapy Ahano-Helera Chemotherapy GI-p-helera		no adjuvant therapy Dhetero>homo (-)	Chemotherapy homothetera (Chemotherapy LL-) homothetera					Immunotherapy Y /- Phetero	mmundherapy Al. Prietero		Immunatherapy Hismony (-), helero Immunatherapy NGP (homo) Indiana	SICHBECH	lotal (nomo)	Treatment Effect
***************************************	Chemotherapy TT(58)	no adjuvant therapy EL (90 9) Chemotherapy AL (95 1) Immunotherapy AE (67 5)	Chanotherapy AA (59)	no adjuvant therapy ER/917, Chemotherapy As/77.8)	no adjuvant therapy DQ (86,5)	Chemotherapy II(74.8)			no adjuvant therapy SV(100) immunotherapy AD(83.3)	Chemotherapy FF(74.5)			Immunotherapy NS(69-1)			Stomach cancer	Treatment Effect

Fig. 58

			Treatment Effect	Treatment Effect	Treatment Effect	DR	DR	DR	D _R
	Diversity	Equivalence	Total (+) vs (-)	Total (homo)	Other cancers	Cancer in Family	Metasiases	Total t(ratio of advanced cancer)	
DR E	Diversity		Other cancers	Other cancers	a fee a				
Ğ	⊋	X=73					2		
		F.,.					F180112290		•• .4
		A=T			,,,,,,				
		A=V					25 = 4		• • • •
arp 1 /	AS	AES			no adjuvant therapy AA(100)		- 2 = 4		wi
		Q≈R			42				
		9K=11D=26Y		no adjuvant	no adjuvant therapy KW(88 9)		****		
		=28H=30G		therapy Whetero (-) >honio					
arp10	EQY	10E=31V=38A							
****	···	=(166R)	**		** ***		•		
arp11 : 0	DGLPSV	11G=13Y=14		no aduvant					
		E=14=K25Q=	*****	therapy Phatero (-)	,,		2 × 4 4 2 .		
		118=40%=40T	÷.com	2 ngmo					
		.13P=13R	obstation (•••
	4		Action of the stability	on contract the contract to th		يا ميايات و کارون و کارون او کارون و ک		and the second s	4
	FGHRSY	13F=31F=31	****************	no adjuvent therapy Rhelero (>Hono Chemotherapy	no adjuvant therapy FR(90) Chemotherapy FR(72) Immunotherapy FS(100)			FT22.6, FF0, GR0, O	
21712816281	21852#152#11		******************	Shetero (Jishomo Immunotherapy Sheteros (Jisomo					
	*	m [±] X					**		3-3-3
	HOY		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,					QQ100, YY6, 3O	i.,,,,
		Q.R				and desirable that has the state do the same do seek do the same do the			زريا
******			*********	Chemotherapy F(-) (hetero)>homo			44:		
	DEH	28H≈30G	oskoossi o	Chemotherapy heliero (p-homo	Chemotherapy EE (0)		*		
	ŔRY	30H=37L=38L =85A=85V			20144				,
arp31	FIV	31V=38A=40F					wate		

Fig. 59

	묾	arp32	30.23	arp33	arp37	arp38	arp40	arp47	arjp57	arp58	arp60	arp67	arp70	arp71	arp73	arp74	alp//	arp78
Diversity	Diversity	¥	LE CONTRACTOR	Z	FLNSY	ALV	FΥ	FΥ	ADSV	À	Ϋ́	골	DOR	AEKR	å	AELQR	: 5%1	₹
Equivalence		H≈γ	CI-XI		F#S		F=Y	F=Y		A=E					73A=73G=74 R=74N=77N= 77T	R=N	1 - K.	
Total (+) vs (-)	Other cancers	Chemotherapy Y(+)>(.) Immunotherapy Y(+)>(.) Chemotherapy H(-)>(+)							Chemotherapy A(-) > (+)							no adjuvani therapy Li-		
Total (homo)	: Other cancers	Chematherapy Hi-),hetero-homo immunicherapy hetero ()-homo Chematherapy hetero homo×(-)	Theisro horron		Chematherapy Ft.), the let of hamaing adjuvant the rapy Shetero ()-hamai				Chemotherapy A4 >> (helera) hamo minundifierapy Shelera (-)-hamo		Chemollierapy H			no adjuvant therapy Ahetero (-1)-hono		no adjuvani therapy Aftelero (17 homo	, , , , , , , , , , , , , , , , , , ,	
Other cancers		Chemotherapy HY(55.6), Immunotherapy HY(55.6)			no adjuvent therapy YY(81.3), Chemotherapy FS(100), Immunotherapy NS(80)	***************************************			no adjuvant therapy SV(81.8). Chemotherapy VV(85.7). Immunotherapy DS(78.8)		Chemomerapy SS(35.7), immunotherapy H1775)	no adjuvent therapy FF85.7 IL76.3		no adjuvant therapy AR (74.9)		no adjuvant therapy (AE81). Chemotherapy (AE54.4)		,
Cancer in Family	***************************************			ONE CALLES AND		*							,		SS # 118 . 118 .			•
Metastases	***			or description of the second s		and the second of the second o						(33446234		6 m + 1 / 3 (m m			***************************************	•
Total t(ratio of advanced	udi Kal		LANCE OF KIND OF	HW18 3 NW0 80		Appendix and Appen								••				
Smoking										***************************************								

Fig. 60

A				arp181 MT					arp142 MV	arp140 AT	arp133 LR	arp120 NS	arp104 AS	arp98 EK			arp85 AV	- 1	ğ	and the second second
A		D=Q		e consession esta				7 0=H	/ M=V							, G=V	AV A=)	ersity	Diversity Equ	ş.
	₩	Q	S	***************************************		20		٥	<	***************************************	133L=133R=1 42M=142V	Z	Ø	98E=98K=104 A=104S		<		and a descript a descript a descript	Equivalence	
	Immunotherapy T(+)+(-)			P. 4 4 5 3 4 4 5 5 5 4 5 5 5 6 5 5 5 5 5 5 5 5 5 5			residente de la companya del companya de la companya del companya de la companya del la companya de la companya		no adjuvant therapy VEFEL		no adjuvant therapy R(+)>(-)		Immunotherapy \$(+>(-)	Immunotherapy KI+57.)		Chemotherapy G(+):-(-)		Other cancers	Total (+) vs (-)	President and Co. and
	Immuratherapy Rhelera ()-homo Immuratherapy hetero rumus) (no adjuvent therapy Mhetero (un homo ino adjuvent therapy Vhomo heteron) (i		no adjulant flerapy Litetero i Promo ino adjulant flerapy Rhomo heteroviki		Immunotherapy Ahetero (-)-homo, immunotherapy Shetero homo>(-)	inmurotherapy Eneteral-)-homo immunotherapy Klietem homo>(-)	no adjuvant therapy Qi-) haterostomo	Chemotherapy Ghomotreserance		: Other cancers	Total (homo)	
	Immunotherapy RT(77.9)				no adjuvant therapy LV(100)	•			ns adjuvent therapy VV(69-1)		no adjuvant therapy FR(69-1)		Immunotherapy AS(81.9)	Immunotherapy EK(68.4)	no adjuvant therapy HY(100)	Chemonerapy (VVI90)			Other cancers	
		,	· · · · · · · · · · · · · · · · · · ·		*	,	,					*					2 8 7 2 0		Cancer in Family : Metastases	to the same and th
		***************************************	***************************************							,						**		The state of the s	Metasiases	Secretaria de la constante de
		· · · · · · · · · · · · · · · · · · ·	· contraction cont				***************************************				,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	**			*			2 2 9 000 000 000 000 000 000 000 000 00	Total (ratio of advanced cancer)	con promise and accommendation accommendation
MEEL				**			***************************************						., ., ., ., ., .						Smoking	and an analysis of the same of

Fig. 61

			105 :	8	š	88	š		85	£	larera.	<u></u>	37			
app86	28cqs	app84	app76	аррбэ	app65	app57	app56	арр55	app36	app35	app11	арр9	аррв	Pe		
Αp	EG G	g	Z.	#	됥	DE.	Æ	ADE	AV	FLY	ତ	FHY	Ŋ	Diversity		
~~		•• `		m *	651=651				A=V		GH.		8L=8V=9F		Equivalence	.,
							~		*****			, see		Fotal	Total (+)	Flognosis
	• • • • •	• • • •							*************************					Total	Total (homo)	Friograpsis
AP66.9	EG66.9	DG66.9	#100	EK68.6	LL85.7	DD68.5	EE67.5	AA85.7	AA85.7	FF68	GL87.3	FY68.2	LV67.4	Total		2,000
		• • • •	* * * * * * * * * * * * * * * * * * *		O PARTICIONAL DE SANTOS DE LA COMPANSION		,		A Property and the analysis and the same and					Stomach	Total (+) vs	Stechtigotta
	•••	***			***************************************								3 414	Stomach	Total (homo)	C. OGNOSIS
PP70.8	: GG70.8	: GG70.8		EX69.4	11.85.7	DD76	EE70.8	AA80	AA80	FY7690	LL77.8	: YY85.7	VV77.8	Stomach		Ç.
~^	,	,,,,			***************************************				*****					Other	Total (+) Vs (-)	riognosa
	****				***************************************	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,						***		Cancers	Total (homo)	Stentiforu
AP65.9	EG85.9	: DG85.9	IM67.70	EX67 90	IL64.6	EE64.2	AA67.3	AA100	AA100	1,489.8 1,899.73	000 84 6	PY65.80	1/6470	Other		
	****					-								Total	Total (+)	Effect
7	->**	7***		no adjuvent herapy Ehetrooy 21 homo no adjuvent herapy Kheterooyh			***************************************		-		>>+ 4 ; > •			Total	Total (homo)	Effect
*	.,	.,		no adjuvam therapy EK (81.4)				acjuvare Therapy				,,,,			All cases	

Fig. 62

	207	199	125	116	-			
Overall Progno sis	app178	app170	app96	app87	distribution and	ş		
More than 3, all survived	LW.	-	歪	NAN.	-	Diversity		
							Equivaience	
	***************************************				adord a control of	Total	e Total (+) vs (-)	Prognosis
					· · · · · · · · · · · · · · · · · · ·	Total	Total (homo)	Sisoniform
DP9YY(5)	LM70.6	11100	XX100	6 99AM	a afficial de mandra de mandra de mandre de mandra de ma	Tota:		00000
	*******************************					Stomach	Total (+) vs (-)	Sisongory
					.	Stornach	Total (homo)	Prograsis
DP65LL(MM75	=100	XX100	MM70.8	ł	Stomach		g
		****			cancers		Total (+) Vs (-)	j
					cancars	Other	Total (homo)	SisouGora
	LM70.5	1765.3	KR65.3	MV65.9	cancers	Officer Officer		Frograsis
	***************************************				**************************************		Total (*) Vs (-)	Effect
					•	iotai	Total (homo)	Effect
200		 		·	**************		·	E 7

Fig. 63

		арр76	994де	арр65	app57	арр56	арр55	аррЗб	app35	app11	арр9	аррв	Dp	
Ap	DG	AWK	m ×	79	DE	À	ADE	AV	YJR	GL	YH?	7.3	Dwers#y	
			minimotherap y E (->(+)	NOONO NOONO							іттиповетар у Незіч ғу		Stomach	Total (+) vs (-)
		Chematherapy (i.) (homo/shetero	no adjuvant flerapy Ehetero ((-)) iumo, Immuncherapy E- (rietero Phomo no adjuvant florapy Khetero Phomo) (-) Immuncherapy Khomo (netero) (-)				Chemotherapy A() (florid) Helero	Chemotherapy A;) (homo-Netero Chemotherapy Wromo (;)-herero			Immundherapy H;) (hana)-hefero		Stornach	Treatment Effect Total (homo)
		Chemoherapy MV(64)	no adjuvant therapy EK (85.4), immunotherapy (Kr. (58.3)					Chemotherapy (VV)	Chemotherapy (FF)		Immunotherapy FY(67-1) FF(65)			Treatment Effect Stomach cancer
			no adjuvari herapy K (+)>(-)	no adjuvant therapy L (+) (-)	no adjuvant therapy E (+>+;)	no adjuvant therapy A(+)>(-)	-23****			no adjuvant therapy G(+)>(-)	no adjuvant therapy F(+)×(-)	***************************************	Other cancers	Total (+) vs (-)
;		no adjuvant therapy Vhatero () > homo		no adjuvant fibrapy hetero-homo iro adjuvant herapy Lihetero homo iri, no adjuvant herapy thereo-homo iro adjuvant herapy there iro adjuvant herapy there iro adjuvant iro ad	no adjuvant therapy Chelero (, Aromo no adjuvant therapy Enetero homo>)	no adjuvant therapy Anatemay i homo, no adjuvant therapy Eheteroni homo	no adjuvant therapy Dhetero-rijhomo			no adjuvant herapy Grelero homo (1) no adjuvant therapy Li I netero-homo	no adjuvant therapy Thelera tromp>+1, no adjuvant therapy Hi Thelero-Homo	no adjuvant therapy Vhetero i juhamo	Other cancers	Treatment Effect Total (homo)
AAAAA AAAA AAAA AAAAA AAAAA AAAAA AAAAA AAAA		no adjuvani therapy MV(79)	no adjuvant therapy EK(71.7)	no adjuvem therapy (L/100)	no adjuvani therapy DE (76.6)	no adjuvant herapy AE774 8)	no adjuvant therapy DE(76.3)		Chemotherapy (LY)	no adjuvant therapy(GL)	no adjuvant therapy (FY)	no adjuvani Iherapy (LV)		Treatment Effect Other cancers
EE92 - CC87 50	ėm:	VV95 6 1166 70			VV96.3 (LI99.6.C)					VV85.211.89.RO	#	W95.2 LL89.50	malignancy)	Category (rate of
							O 48 4410	#						Metastases

(Cut-off data added as was present in Figure as originally filed)